Agentic pipelines land in drug discovery
-
Nº LXIV
- Date
- 28 Jul 2026
- Issue
- 64
- Stories
- Eight
- Editor
- ARC
Tuesday brings the shift we've been circling for a year: agentic workflows moving from demo to default, with the infrastructure debate right behind.
Muni Bio runs autonomous discovery pipeline
Muni Bio ran an early-stage drug discovery pipeline designed and executed autonomously by agents, walking through target selection, hit generation, and prioritization end-to-end in a public writeup. The lab is betting the default shape of early discovery flips from human-driven with AI assists to agent-driven with human review. It's one of the first end-to-end demonstrations from an operating drug-discovery outfit, not a benchmark-only paper.
The physical layer of autonomous science
Autonomous discovery's bottleneck isn't the model, argues a widely-shared thread — it's the physical layer connecting agents to instruments, reagents, and robotics. The frame reframes the competitive frontier away from pure LLM benchmarks toward wet-lab integration, and lines up the automation-hardware stack as the next contested budget item in bio-AI — the same argument DeepMind made last week.
Plato-Bio benchmarks novelty claims
Plato-Bio verifies biological novelty by rediscovering known findings from time-sliced literature, then scoring structural plausibility of new proposals. The setup turns "our agent discovered something new" from a marketing claim into a checkable one, and anchors a reference benchmark for the flood of autonomous-discovery papers now landing weekly.
Agent debugs ECG classifiers by failure
An evidence-driven agent recursively refines ECG classifiers by examining what the model gets wrong, not just its aggregate metrics. Moves clinical-ML iteration from human-audited error analysis to an agent-driven loop — narrows the gap between research-grade classifiers and the failure-mode discipline clinical deployment actually requires.
STAR Suite ships single-binary transcriptomics
STAR Suite bundles reproducible transcriptomics processing into a single executable designed for AI-agent orchestration. Raises the floor for what "agent-ready" bio tooling looks like — no environment hell, no dependency drift, one binary an agent can call.
MetaClaw audits metagenomic analysis
MetaClaw runs metagenomic and multi-omics analysis end-to-end with a built-in audit trail, logging every decision the agent makes. Provenance-by-default in an omics agent — moves auditability from a compliance afterthought to a design constraint, which is where any clinical or regulatory adoption starts.
Anthropic stakes open-weights position
Dario Amodei laid out Anthropic's position on open-weights models, framing when release is safe and when it isn't. Sharpens the policy debate the field will inherit as open-weight biology models keep shipping from Chinese and academic labs.
Claude Opus 5 lands
Anthropic shipped Claude Opus 5 , pitched as a step change for long-running agents plus coding and professional work — the tier most bio agent builders default to when reliability across many tool calls matters more than latency.
Reply with your discoveries. A human reads them. Forward freely.
|